Daratumumab（Anti-CD38）是一种靶向CD38的IgG1型单克隆抗体，通过干扰多发性骨髓瘤细胞的黏附功能，增强其对蛋白酶体抑制剂的敏感性，从而发挥抗骨髓瘤作用。

Purity

Anti-CD38 Reference Antibody (daratumumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
SEC-HPLC

The purity of Anti-CD38 Reference Antibody (daratumumab) is 98.99%, determined by SEC-HPLC.
ELISA

Immobilized human CD38 NHis at 2 μg/mL can bind Anti-CD38 Reference Antibody (daratumumab), EC50=0.04792 μg/mL.

FACS

Human CD38 CHO-S Cell Line were stained with Daratumumab and negative control protein respectively, washed and then followed by PE and analyzed with FACS,EC50=1.264 nM.

-25~-15℃保存，有效期1年。